8 ClinicalTrials.govNCT02637284 PCO-02: Phase I safety and pharmacokinetics trial of oral BPC-157 (early-stage human study)
Many people taking semaglutide for weight loss experience a significant reduction in body weight, which can lead to improvements in other health areas as well
A higher dosage of Wegovy may be associated with greater weight loss but can also result in more noticeable side effects than Ozempic, however, these remain fairly mild
Finally, we show that in women taking either semaglutide or tirzepatide, elevated circulating estradiol levels are predictive of nausea and vomiting risk
Start with the lowest dose to minimise GI side effects and titrate based on patient tolerance
Be transparent about your eating behaviours, including any binge eating, emotional eating, or disordered eating patterns